Latest Biotech News

Page 6 of 42
Prescient Therapeutics boosted enrolment in its PTX-100 Phase 2a trial to 28 patients and appointed Dr Rosalind Wilson as Chief Medical Officer, strengthening its clinical leadership as it advances targeted cancer therapies.
Ada Torres
Ada Torres
27 July 2026
Arovella Therapeutics secured ethics approval and manufactured its first clinical batch of ALA-101, targeting blood cancers, while progressing its solid tumour program and refining autoimmune strategies. The company ended the quarter with $14.4 million in cash, supporting imminent clinical milestones.
Ada Torres
Ada Torres
27 July 2026
Patrys Limited is pushing forward with a proprietary injectable formulation of quetiapine targeting the lucrative delirium treatment market, leveraging a faster, lower-cost FDA 505(b)(2) regulatory pathway and strong patent protection.
Ada Torres
Ada Torres
27 July 2026
Argenica Therapeutics is gearing up for a pivotal late-stage clinical trial of its neuroprotective drug ARG-007 (xaranetide) in acute ischaemic stroke, backed by strong safety assays and solid funding.
Ada Torres
Ada Torres
24 July 2026
Papyrus Australia has tapped related party L39 Capital to lead a capital raise and secured an interest-bearing $200,000 loan from Irwin Biotech, with conversion into shares and options pending shareholder approval.
Victor Sage
Victor Sage
22 July 2026
Ceretas Limited is raising $8 million through an IPO to fund clinical trials and development of its novel therapeutic ultrasound device targeting Alzheimer’s disease symptoms.
Ada Torres
Ada Torres
21 July 2026
Marlin Global's portfolio delivered a 2.0% gross return in Q2 2026, driven by rebounds in ICON and semiconductor holdings, but lagged a strong US market rally led by AI and chip stocks.
Victor Sage
Victor Sage
20 July 2026
Mesoblast has completed treatment of 300 patients in its pivotal Phase 3 trial for rexlemestrocel-L, targeting chronic low back pain due to degenerative disc disease, with topline results expected mid-2027.
Ada Torres
Ada Torres
14 July 2026
Imugene has secured $11.12 million through a placement to advance its allogeneic CAR-T therapy azer-cel after early clinical data showed complete responses in BTKi-resistant lymphoma patients.
Ada Torres
Ada Torres
7 July 2026
Noxopharm has taken a key regulatory step by requesting a pre-IND meeting with the US FDA for its autoimmune drug candidate SOF-SKN, aiming to smooth the path for clinical development and boost its commercial appeal.
Ada Torres
Ada Torres
7 July 2026
Zoono Group has reported a 94% jump in quarterly cash receipts to NZ$975K, turning cash flow positive amid expanding commercial rollouts of its shelf-life extension technology across multiple continents.
Ada Torres
Ada Torres
7 July 2026
Associate Global Partners has partnered with US investment manager ARK to bring the ARK Venture Fund to Australian wholesale investors, expanding AGP's access to high-growth private companies focused on technological disruption.
Claire Turing
Claire Turing
3 July 2026

Browse the archive

Full archive